The efficiency of UPOINT-based multimodal therapy for patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) was assessed, and parameters that may be related to clinical improvement were identified by researchers for a study.

Patients with CP/CPPS participated in the retrospective research that was carried out. Patients were categorized using the UPOINT phenotyping system to direct their multimodal treatment. NIH-CPSI scores were calculated at the start of treatment and three months later, and clinical improvement predictors were evaluated.

After therapy for 3 months, there was a substantial improvement in the overall NIH-CPSI, with a mean reduction of 8.21 (P< .001). After 3 months of therapy, 66.2% of patients saw a clinical improvement as measured by a total NIH-CPSI score drop of at least 6 points. There was no evidence of a relationship between clinical improvement and the degree of pain (ORa = 1.198, 95% CI 0.392-3.662, P =.751), the initial total NIH-CPSI (ORa = 0.983, 95% CI 0.886-1.089, P =.738), the number of positive UPOINT domains (ORa = 0.871, 95% CI 0.451-1.681, P =.681), and number of prescribed therapies (ORa = 1.118, 95% CI 0.699-1.789, P = .641).

The CP/CPPS had significantly improved as a result of UPOINT phenotyping and guided treatment. Age or race didn’t seem to affect how well a treatment works. Additionally, neither the initial scope and severity of the illness, as measured by the NIH-CPSI, the number of positive UPOINT phenotypes, nor the number of medicines used in the multimodal treatment approach, were predictive of clinical improvement.